The Longevity Reality Radar
46 approaches, rated by evidence.

CAR-T for lupus and autoimmune disease

CD19 CAR-T immune 'reset' for lupus & autoimmunity. Autoimmune disease. Reviewed Jul 2026.

Drug-free remissions lasting past one to two years in small cohorts, with durability and infection risk still under study.

Stage
Phase 1/2
Rung: In human trials. Phase 1 to 3. Being tested in people now. Most will not make it.
Evidence grade
C
small cohorts
Small or uncontrolled human data, or strong animal data. How grades work.

What it is

The cancer CAR-T approach repurposed to delete the rogue B-cells driving autoimmune disease, letting the immune system rebuild itself healthy.

The evidence

Early cohorts show sustained drug-free remission past 1–2 years with B-cells returning naïve. Small numbers; long-term durability and infection risk still under study.

What you can do today

Outside a registered clinical trial, this is not something you can responsibly get. If it is relevant to you, the route is a trial: ask your specialist, or search a trial registry such as ClinicalTrials.gov for studies you may qualify for.

Sources

Change history

No ladder moves or corrections logged for this entry yet. Changes are dated on the change log.

Related

More in Autoimmune disease

  • Off-the-shelf CAR-T (TyU19)Grade C, early patients. Phase 1.Donor cells cleared B cells and produced deep remission in early patients, with only six months of follow-up.